.png){kind=icon}
.png){kind=icon}
Return
TQB2450 plus intensity-modulated radiotherapy in recurrent nasopharyngeal carcinoma: An open-label, single-arm, phase II trial
.png){kind=icon}
OA
AI
T
W
刘
Z
S
X
L
W
丁
A
L
唐
X
Y
R
M
DOI：10.1016/j.medj.2025.100846.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
• TQB2450 plus IMRT is effective and well tolerated in rNPC • Lower baseline TCR diversity in blood is associated with improved PFS • Serial monitoring of EBV DNA levels predicts PFS outcomes • High MIF expression in tumors and a cold TME correlate with poor PFS
Keywords:
nasopharyngeal carcinoma
anti-PD-L1 antibody therapy
intensity-modulated radiotherapy
TQB2450
MIF
Translation to patients
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
11.8
Papers:
771
Citations:
2.2K
Organization
Cited Papers